Skip to main content

Targeting leukaemia by modulating hematopoietic stem cell competitiveness

Project description

Targeting leukemic stem cells

Acute myeloid leukemia (AML) remains a devastating disease with less than 30 % of patients surviving five years after diagnosis. The resistance of AML is driven by small subpopulations of leukemic stem cells (LSCs), which survive chemotherapy and elude immune surveillance. LSCs have growth advantages induced by oncogenic mutations but are in many ways similar to healthy hematopoietic stem cells (HSCs). LSCs are located in protective bone marrow niches promoting stemness and therapy resistance and modify these to displace HSCs for their own expansion. The EU-funded Hemstem project explores strategies to target LSCs based on the knowledge of the complex interactions between LSCs and HSCs and provides a rationale for novel treatments.

Field of science

  • /medical and health sciences/medical biotechnology/cells technologies/stem cells

Call for proposal

ERC-2019-COG
See other projects for this call

Funding Scheme

ERC-COG - Consolidator Grant

Host institution

EBERHARD KARLS UNIVERSITAET TUEBINGEN
Address
Geschwister-scholl-platz
72074 Tuebingen
Germany
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 739 846,25

Beneficiaries (2)

EBERHARD KARLS UNIVERSITAET TUEBINGEN
Germany
EU contribution
€ 1 739 846,25
Address
Geschwister-scholl-platz
72074 Tuebingen
Activity type
Higher or Secondary Education Establishments
UNIVERSITAT BASEL

Participation ended

Switzerland
EU contribution
€ 244 393,75
Address
Petersplatz 1
4051 Basel
Activity type
Higher or Secondary Education Establishments